Significance of Arrhythmias During the First Background Although early intravenous p-blocker therapy during acute myocardial infarction (AMI) reduces the incidence of fatal arrhythmias in patients not treated with thrombolytic agents, its antiarrhythmic effect in thrombolysed patients remains controversial. We investigated prospectively the arrhythmia incidence in 244 patients with AMI receiving alteplase and a double-blind randomized adjunctive therapy with intravenous atenolol, alinidine, or placebo. Moreover, the characteristics and prognostic significance of early arrhythmias and their relation with infarct size and coronary patency were evaluated. Methods and Results All patients underwent 24-hour Holter monitoring on day 1 and were clinically followed in the hospital for 10 to 14 days. Coronary angiography was performed on day 10 to 14. Atenolol and alinidine significantly decreased the basic heart rate without causing more sinus arrest or higher-degree atrioventricular block. The prevalence of atrial fibrillation in alinidine patients was lower than in the atenolol patients (P=.007) but not lower than in placebo patients (P=.11). There was no effect of either agent on the incidence and frequency distribution of ventricular or supraventricular premature beats or on the incidence and characteristics of nonsustained ventricular tachycardia, accelerated idioventricular rhythm, sustained ventricular tachycardia (VT), or ventricular fibrillation (VF). On day 1, seven VF episodes were recorded in six patients (2.5%) and five VT episodes in five patients (2%). VF always started at <2.5 hours after start of thrombolytic treatment and VT always at >2.5 hours (average of 6 hours). Five of the seven VF and three of the five VT episodes started with an R-on-T. However, for all VT, the morphology of the first beat was the same as that of the following beats, suggesting that the sustained arrhythmia was not induced by an extrasystole. After day 1 and before hospital discharge, VF and VT developed in one and six patients, respectively. Three of the seven patients who developed VF during the first 2 weeks underwent coronary angiography; all three had an occluded infarct-related artery. In contrast, only one of nine patients with early or late VT had an occluded vessel. Patients with VT and VF on day 1 had a significantly larger enzymatic infarct size than those without the arrhythmia (P=.02), and a similar trend was noted for VT or VF after day 1 (P=. 19 ). However, none of the patients with VT or VF on day 1 developed a life-threatening arrhythmia later during the hospital stay. Also, none of the seven patients with VT or VF after day 1 had experienced a major rhythm disturbance during the first 24 hours.
Conclusions (1) Our data do not support the hypothesis that ,B-blockers or bradycardiac agents might reduce the incidence of major arrhythmias when used in conjunction with thrombolytic therapy. ( 2) The pathogeneses of VT and VF early during AMI are clearly distinct. (3) VT or VF during the first 2 weeks is a marker for a larger infarct. (4) We could not detect a relation between malignant arrhythmias on day 1 and recurrences within the following 2 
Other Investigations
In addition to the Holter recordings during the first 24 hours reported here, enzymatic infarct size, coronary angiography and left ventriculography (with calculation of ejection fraction), scintigraphic left ventriculography, and exercise testing were performed within 10 to 14 days in all patients. The methodologies used for these additional investigations have been described previously.7,9 10 The study data form, which had to be filled out by the responsible clinician, also asked for the presence of major arrhythmias (sustained VT and VF) during the hospital stay.
Follow-up
The end point of this substudy was a comparison of the incidence of bradyarrhythmias and tachyarrhythmias within the three treatment groups during the first day. In addition, we wanted to evaluate whether arrhythmias documented during the first 24 hours were correlated to arrhythmic events or outcome later during the hospital stay. Moreover, since STsegment normalization and accelerated idioventricular rhythms (AIVR) might predict the presence of reperfusion, we wanted to investigate in which percentage of cases these signs were detectable on Holter recording and whether they were correlated with the angiographic findings.
Definitions
Ventricular or supraventricular premature beats (VPB and SPB) were defined as being >20% premature and wider (or not, respectively) by more than 25% in either or both Holter channels. VT was defined as three or more consecutive VPBs at a rate of .120 beats per minute. It was considered sustained if it lasted more than 30 seconds or required DC cardioversion because of hemodynamic collapse. Accelerated idioventricular rhythm was defined as three or more consecutive VPBs at a rate of <120 beats per minute.
Statistical Methods
As pointed out in our previous report,7 the goal of the study was to investigate how ,-blockers might be beneficial when used early during myocardial infarction, the primary end points being global and regional left ventricular function and infarct size. The arrhythmia evaluation was added as a secondary end point. Every patient was prospectively planned to have a Holter recording as part of the original study protocol, and all patients with analyzable Holter recordings are part of this study. The sample size, however, was calculated on the basis of the expected treatment effect on the primary end points (ejection fraction), based on three treatment groups (power, 80%; a=.05).7 Given our data and assuming expected treatment benefits from previous studies with ,B-blockers of 30%,45 14 and for an a=.05, we calculated the power of our Holter substudy for some variables (using a categorized approach and three treatment groups): it is 83% for runs of nonsustained VT, 24% for runs of AIVR, and 27% for the average number of VPBs per hour. To have an 80% power for the last two variables, the treatment effect had to be 60%; hence, reductions or increases of the number of AIVR or of VPBs <60% may have been unnoticed by our analysis.
Continuous data are presented as mean+SD if normally distributed; otherwise, the median and 90% range are reported. For categorical data, the three treatment groups were compared by an extension of the Fisher's Exact Test. For continuous measurements, a one-way ANOVA was performed if the (possibly transformed) data appeared to be normally distributed in each group. Normality was assessed by the Shapiro-Wilk test. If a normalizing transformation could not be found, the Kruskal-Wallis test was used. For correlation analysis of the ranks of variables, Spearman correlation coefficients were calculated. In all other cases, pairwise signifi- (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) ... NS Antiarrhythmic drugs on day 1, n (%) 23 (27) 27 (33) 19 (25) 69 (28) ... NS Antiarrhythmic drugs after day 1, n (%) 12 (14) 9 (11) 11 (14) 32 (13) ... cance tests combined with a Bonferroni correction were used.
The nominal significance level was fixed at P<.05.
Results

Patient Characteristics
From June 1988 through December 1990, 244 patients with an acute myocardial infarction underwent 24-hour Holter recording starting at the beginning of the administration of alteplase. In addition, 83 received atenolol, 84 alinidine, and 77 placebo. Table 1 lists their baseline characteristics: the three groups were similar with respect to age, sex distribution, incidence and site of previous infarction, systolic and diastolic blood pressures, incidence of diabetes mellitus, time interval between start of the pain and initiation of thrombolytic therapy, pulse rate and serum potassium concentration on admission, enzymatic extent of the present infarction, and ejection fraction (as measured on day 10 to 14). The mean ambulatory ECG recording time was similar in the three treatment groups (overall median of 23 hours and 48 minutes). The proportions of patients receiving antiarrhythmic drugs (mainly lidocaine) during the first 24 hours, or after day 1, were not statistically different. All but one patient, randomized to atenolol, received the study drug. Seventy-three percent of the patients in the atenolol group and 86% of the alinidine patients tolerated the full intravenous dose.
The 244 patients formed a subgroup of 292 patients described in a previous report on left ventricular function, infarct size, and clinical outcome among the three treatment groups.7 Dropouts from the Holter study were a result of technical failure, nonavailability of the recorder, or death early after randomization (17 in the atenolol arm, 14 in the alinidine arm, and 17 in the placebo group). (P=.08). However, the proportion of patients with sinus arrest causing pauses of 3 seconds or more (eventually with junctional escape) was not different among the three groups. The incidence of atrioventricular nodal block was also similar in the three treatment groups ( Table 2 ). The incidence of intraventricular conduction disturbances, defined as a QRS duration of .120 milliseconds, was comparable for the three treatment groups (overall mean was 3.3%; Table 2 ). Ninety-six percent of the patients remained in a sinus basic rhythm throughout the first day after admission; the remaining 4% had atrial fibrillation during the whole first 24 hours or had self-terminating bouts of this arrhythmia. The prevalence of atrial fibrillation was significantly lower in the alinidine group than in the atenolol patients (P=.007), but the difference did not reach statistical significance compared with the placebo group (P=.11). The enzymatic infarct size and ejection fraction were not significantly different between patients with atrial fibrillation and patients with sinus rhythm. Major ventricular arrhythmias (sustained VT and VF) or death within the first 14 days occurred in 2 of the 10 patients with atrial fibrillation (20%) and in 6.4% of the patients with sinus rhythm (15 of (Table 3 ). There was no difference among the three treatment groups, nor was there any difference in the number of ventricular couplets. The frequency distribution for VPB is listed in Table 3 : half of the patients had a mean number of <10 VPBs per hour. Table 3 also shows the mean number and the frequency distribution of SPBs in the different treatment groups and in the whole population: again, no significant differences were present.
Nonsustained Ventricular Tachycardia
Of the 244 patients, 184 (75%) had at least one episode of nonsustained VT on their Holter recordings; the incidence was similar in the three subgroups (Table  4) . Among the patients who had runs, the number ranged from 1 to 78 (90% interval) over a 24-hour period (overall median was 7). The number of runs of nonsustained VT did not differ statistically among the treatment groups either when calculated for all (244) patients or only for the 184 patients with at least one run. The median length and the rate of the longest run of nonsustained VT were 9 beats (90% range, 3 to 29) and 150 beats per minute (90% range, 120 to 200) for the whole group; they were similar in all subgroups. The frequency distribution of the VT rates is also listed in Table 4 : although the majority of VTs are faster than 150 beats per minute, only 6% of patients had runs that were faster than 200 beats per minute. There was a trend toward fewer runs with a rate of >200 beats per minute in the atenolol group, but it did not reach significance (P=.09). Self-limiting episodes of polymorphic VT were recorded in 4.5% of patients.
Accelerated Idioventricular Rhythm
Of the 244 patients, 174 (71.3%) had at least one episode of AIVR on their Holter recordings. There seems to be a trend toward a lower incidence of runs of AIVR in the placebo group, but this difference was not statistically significant (P=.08) ( Table 5 ). Among the patients with at least one run, the median number of runs of AIVR was three over a 24-hour period (90% range, 1 to 65); it was similar for the three groups. The frequent competition with normal sinus rhythm (in at least 40% of cases) precluded an accurate determination of the length (in number of beats) or duration (in minutes) of the runs of AIVR. In half of the patients with AIVR, bouts of arrhythmia were present for more than 30 minutes (eventually in competition with sinus rhythm). Since there is frequent waxing and waning of the rate of AIVR, we determined the minimal rate of the longest run: it was 80 beats per minute for the whole group (90% range, 58 to 100) and was very similar in the three subgroups. The frequency distribution of the minimal rate of AIVR shows that the vast majority of episodes is slower than 100 beats per minute (93% ;  Table 5) . Surprisingly, 5.3% of the broad-QRS tachycardias with a rate of <120 beats per minute -our definition for AIVR -were reported to have a polymorphic appearance.
If the longest run of AIVR was associated with a concomitant ST-segment normalization of >0.1 mV 
Sustained Ventricular Tachycardia and Ventricular Fibrillation
Sustained VT was recorded in five patients (2%): two receiving atenolol, one receiving alinidine, and two on placebo (not significant). Three of the five episodes started at the end of the preceding T wave and two late after it. The average time period between start of treatment and occurrence of the VT was 6 hours; the earliest episode occurred after >2.5 hours. All episodes were monomorphic, and the morphology of the first beat always was similar to that of the consecutive beats. The rate of the five tachycardias was 170, 150, 145, 135, and 126 beats per minute; the 135-beat per minute episode showed waxing and waning of the rate; the average duration was 6 minutes 52 seconds (the shortest episode lasted 35 seconds), indicating that these VTs were hemodynamically well tolerated. Only one tachycardia required DC cardioversion (after about 13 minutes of tachycardia). None of the patients with early VT developed a life-threatening arrhythmia later during the hospital stay, and none of them died during this time period. Six patients (two from each group) developed VT after the first day; none of them had shown major rhythm disturbances during the first 24 hours.
Seven episodes of VF were recorded in six patients (2.5%): two in atenolol patients, one in the alinidine group, and three in the placebo group (one patient with two episodes) (not significant). All episodes required electrical defibrillation. Six of the seven episodes developed within the first hour after start of treatment and one after 2.5 hours. Five of the seven episodes started with a VPB on or shortly after the preceding T wave. One of the VF episodes that started late after the T wave first had a slower rate (polymorphic VT; about 220 beats per minute) that degenerated into VF; also, after DC shock, there was first a 15-second slow polymorphic VT (about 100 beats per minute) before resumption of normal sinus rhythm. In three patients, both VF (occurring early) and VT (occurring later on day 1) were present. None of the patients with early VF developed a major arrhythmia after day 1, and none of them died during the hospital stay. One patient of the placebo group developed VF and died after the first day; he had not had major rhythm disturbances during the first 24 hours.
The combined incidence of major ventricular arrhythmias (sustained VT and VF) during the hospital stay was 6.2%. The Of the 244 Holter patients, 225 underwent angiography after 10 to 14 days. All patients were heparinized between the day of admission and the day of angiography. Table 6 lists the arrhythmia incidence and frequency during the first 24 hours according to the patency state of the infarct-related artery stratified according to the TIMI classification. There were no differences in the incidence or in the frequency of VPBs, runs of nonsustained VT, or runs of AIVR between patients with an open or occluded infarctrelated artery.
Three of the six patients who had VF during the first 24 hours underwent coronary angiography; all three had an occluded infarct-related vessel. In contrast, of the five patients who had VT during the first 24 hours, three had angiography, and only one had an occluded infarct-related vessel; this patient also had VF 1 hour before the episode of VT. Interestingly, all six patients who developed VT after the first day had an open vessel. No angiogram could be made in the single patient who had VF and died after the first day.
Applying our noninvasive criteria to assess the time of reperfusion (see above), 31 % of the TIMI class 2 or 3 patients fulfilled the criteria for "presumed reperfusion" during or immediately after thrombolytic therapy. Remarkably, 21% of the patients with an occluded vessel at angiography (performed between days 10 and 14) were also noninvasively diagnosed as having "presumed reperfusion." Discussion Effects of Atenolol and Alinidine on the Incidence of Arrhythmias During Acute Myocardial Infarction Treated With Thrombolysis This study shows that effective drug action is exerted by atenolol and alinidine, as indicated by the significant bradycardiac effect in the active treatment groups. However, we did not find different incidences of ventricular arrhythmias during the first 24 hours or during the first 14 days after the acute event compared with placebo. Hence, our data do not support the hypothesis, raised mainly after the MIAMI4 and ISIS-15 trials, that ,X-blockers might reduce the incidence of fatal arrhythmias when used in conjunction with thrombolytic therapy.
The ISIS-1 and the MIAMI investigators had studied the effect of p-blocker administration during the acute phase of myocardial infarction in patients not treated with thrombolytic agents. In ISIS-1, this intervention reduced mortality from VF within the first 2 days; for the 5778 MIAMI patients, it led to a (nonsignificant) reduction of late VF (between days 6 and 15), although there was no difference in the incidence of VF during the first 5 days. The antiarrhythmic potency of p-blockers without thrombolysis was further evaluated in Holter studies by many authors.1"-"3,'6,17 It is clear that the early use of p-blockers in the absence of thrombolytic therapy significantly reduces nonfatal and fatal ventricular arrhythmias late after acute myocardial infarction, and it is likely that this adjunctive therapy also reduces arrhythmias during the first 24 hours.
Our data do not show any antiarrhythmic effect of p-blockers in thrombolysed patients, either for early events (as analyzed by Holter recordings during the first 24 hours) or for late events (such as clinically reported VT and VF during the hospital phase). The observation that the need for antiarrhythmic drug treatment was the same in the three groups (both on day 1 and later) underscores this conclusion. Our results are in agreement with those of Hohnloser et all8 (reporting on the first Holter study in patients treated with p-blockers and thrombolysis) and of those of the TIMI II-B trial. 6 However, some limitations may have precluded the detection of drug effects on arrhythmia incidence, not only in our study but probably also in others. First, our population was a low-risk group (eg, with a rather low proportion of anterior myocardial infarctions) because of possible randomization to negative inotropic p-blockers and the age limit of 70 years. Second, the sample size for the three treatment groups was based on calculations for the primary end points of the study, LV function and infarct size.7 Hence, the power for some of the comparisons in this arrhythmia substudy may be low. Reductions or increases of 30% in the incidence of nonsustained VT could have been detected with a power of 83%, but to detect changes in AIVR or VPB incidence with a power of at least 80%, for instance, treatment effects had to be larger than 60% (ie, the incidence of these arrhythmias had to be more than halved or doubled). Moreover, treatment effects on the less frequently occurring arrhythmias (particularly sustained VT Our study did not show any significant effect of atenolol on the prevention of supraventricular arrhythmias. This is in contrast with the reported reduction in the incidence of atrial fibrillation in two previous studies,14,20 but it confirms the findings of Norris et al19 that propranolol did not reduce the incidence of atrial fibrillation.
Specific bradycardiac agents like alinidine block the hyperpolarization-activated nonspecific cation current, if, partly responsible for the spontaneous diastolic depolarizations in nodal, atrial, and proximal His bundle cells. Antiarrhythmic actions have been attributed to alinidine in regard to focal arrhythmias originating in these cells. However, antiarrhythmic effects on ischemia-related arrhythmias, caused largely by reentrant mechanisms, are very unlikely.21 Therefore, no a priori effect on arrhythmic events was expected in this arm of our trial. Surprisingly, we found a lower incidence of atrial fibrillation in the alinidine patients. Although we have no basic electrophysiological explanation for this finding, it warrants further study. Moreover, alinidine-treated patients tended to have smaller infarcts compared with placebo and atenolol patients. 7 The trend toward a higher incidence of AIVR in the active treatment groups can be explained by the bradycardiac effect, which increases the probability of AIVR to break through the sinus rhythm, and does not appear to be the expression of a proarrhythmic effect. The same observation was made in the TIMI 1I-B trial.6 Remarkably, the rate of the AIVR runs was not changed by /3-blocker therapy or by alinidine. These reperfusion arrhythmias are thought to be generated by delayed afterdepolarizations in calcium-overloaded cells. Sympathetic stimuli are known to lead to an increased calcium load of the cells (eg, by an increased calcium current). The To the best of our knowledge, this study is the largest series of Holter recordings during evolving acute myocardial infarction. Since there were no statistical differences in the incidence of arrhythmias among the treatment groups, some general conclusions can be drawn. We must, however, take into consideration that 28% and 13% of the patients received antiarrhythmic drugs (mainly lidocaine) during the first 24 hours and after day 1, respectively, although no routine prophylactic use (eg, for nonsustained VT) was recommended in the study protocol. This proportion is comparable to observations in analogous trials.4,6"'1, 23 The incidence of VF is low in our series: 2.5% during the first day and 2.9% within the first 14 days. In previous studies (albeit without the use of Holter recording), it was reported to occur in 2.3% to 5.3% of patients during the first day"',24 and in 2.5% to 15% of patients during the first 2 weeks.22'25-28 The incidence is always lower in thrombolysed patients (eg, in the ISAM study, 4.3% versus 5.3% on day 124; in the ISIS-2 study, 4.4% versus 5.0% within 10 days25), but the very low incidence in our series may also be related to (1) the low-risk profile of our patients as discussed above and (2) a delayed start of the recording, missing the first 2.5 hours of chest pain. 3 The incidence of nonsustained VT (75%) or of AIVR (71%) in our series is much higher than the previously reported data of trials without Holter recording24 or with recording during a limited time period,29 since the benign hemodynamic effect of these arrhythmias may calculated figures in some smaller studies using Holter: 70% to 90% for nonsustained VT22,27,30 and 77% to 90% for AIVR.2227303' A noteworthy observation is that none of the patients with major arrhythmias during the first day had malignant recurrences during the ensuing 2 weeks (and vice versa). The limited size of our study and the low incidence of major events in our low-risk patients, Summarizing, we may conclude that (1) our data do not support the hypothesis that ,-blockers or bradycardiac agents might reduce the incidence of arrhythmias when used in conjunction with thrombolytic therapy, with the possible exception of atrial fibrillation in the alinidine group; (2) the pathogeneses of VT and VF early during acute myocardial infarction are clearly distinct; (3) VT or VF during the first 2 weeks is a marker for a larger infarct; (4) we could not detect a relation between malignant arrhythmias on day 1 and recurrences within the following 2 weeks; and (5) the presence of ST-segment normalization combined with the occurrence of a long run of AIVR predicts coronary reperfusion.
